BACKGROUND: Adding cyclic short sustained inflations (sigh) to assisted ventilation yields optimizes lung recruitment, decreases heterogeneity and reduces inspiratory effort in patients with acute hypoxemic respiratory failure (AHRF). These findings suggest that adding sigh to pressure support ventilation (PSV) might decrease the risk of lung injury, shorten weaning and improve clinical outcomes. Thus, we conceived a pilot trial to test the feasibility of adding sigh to PSV (the PROTECTION study). METHODS: PROTECTION is an international randomized controlled trial that will be conducted in 23 intensive care units (ICUs). Patients with AHRF who have been intubated from 24 h to 7 days and undergoing PSV from 4 to 24 h will be enrolled. All patients will first undergo a 30-min sigh test by adding sigh to clinical PSV for 30 min to identify early oxygenation responders. Then, patients will be randomized to PSV or PSV + sigh until extubation, ICU discharge, death or day 28. Sigh will be delivered as a 3-s pressure control breath delivered once per minute at 30 cmH2O. Standardized protocols will guide ventilation settings, switch back to controlled ventilation, use of rescue treatments, performance of spontaneous breathing trial, extubation and reintubation. The primary endpoint of the study will be to verify the feasibility of PSV + sigh evaluated through reduction of failure to remain on assisted ventilation during the first 28 days in the PSV + sigh group versus standard PSV (15 vs. 22%). Failure will be defined by switch back to controlled ventilation for more than 24 h or use of rescue treatments or reintubation within 48 h from elective extubation. Setting the power to 80% and first-risk order to 5%, the computed size of the trial is 129 patients per arm. DISCUSSION: PROTECTION is a pilot randomized controlled trial testing the feasibility of adding sigh to PSV. If positive, it will provide physicians with an effective addition to standard PSV for lung protection, able to reduce failure of assisted ventilation. PROTECTION will provide the basis for a future larger trial aimed at verifying the impact of PSV + sigh on 28-day survival and ventilator-free days

Mauri, T., Foti, G., Fornari, C., Constantin, J., Guerin, C., Pelosi, P., et al. (2018). Pressure support ventilation + sigh in acute hypoxemic respiratory failure patients: study protocol for a pilot randomized controlled trial, the PROTECTION trial. TRIALS, 19(1), 460 [10.1186/s13063-018-2828-8].

Pressure support ventilation + sigh in acute hypoxemic respiratory failure patients: study protocol for a pilot randomized controlled trial, the PROTECTION trial

Mauri, Tommaso;Foti, Giuseppe;Fornari, Carla;Conti, Sara;RONDELLI, EGLE ROSALIA;Lovisari, Federica;Pesenti, Antonio
;
Grasselli, G
Membro del Collaboration Group
;
Abbruzzese, C
Membro del Collaboration Group
;
Bronco, A
Membro del Collaboration Group
;
Villa, S
Membro del Collaboration Group
;
Gianni, S
Membro del Collaboration Group
;
Pinciroli, R
Membro del Collaboration Group
;
Villa, F
Membro del Collaboration Group
;
Patroniti, N
Membro del Collaboration Group
;
Querci, L
Membro del Collaboration Group
;
2018

Abstract

BACKGROUND: Adding cyclic short sustained inflations (sigh) to assisted ventilation yields optimizes lung recruitment, decreases heterogeneity and reduces inspiratory effort in patients with acute hypoxemic respiratory failure (AHRF). These findings suggest that adding sigh to pressure support ventilation (PSV) might decrease the risk of lung injury, shorten weaning and improve clinical outcomes. Thus, we conceived a pilot trial to test the feasibility of adding sigh to PSV (the PROTECTION study). METHODS: PROTECTION is an international randomized controlled trial that will be conducted in 23 intensive care units (ICUs). Patients with AHRF who have been intubated from 24 h to 7 days and undergoing PSV from 4 to 24 h will be enrolled. All patients will first undergo a 30-min sigh test by adding sigh to clinical PSV for 30 min to identify early oxygenation responders. Then, patients will be randomized to PSV or PSV + sigh until extubation, ICU discharge, death or day 28. Sigh will be delivered as a 3-s pressure control breath delivered once per minute at 30 cmH2O. Standardized protocols will guide ventilation settings, switch back to controlled ventilation, use of rescue treatments, performance of spontaneous breathing trial, extubation and reintubation. The primary endpoint of the study will be to verify the feasibility of PSV + sigh evaluated through reduction of failure to remain on assisted ventilation during the first 28 days in the PSV + sigh group versus standard PSV (15 vs. 22%). Failure will be defined by switch back to controlled ventilation for more than 24 h or use of rescue treatments or reintubation within 48 h from elective extubation. Setting the power to 80% and first-risk order to 5%, the computed size of the trial is 129 patients per arm. DISCUSSION: PROTECTION is a pilot randomized controlled trial testing the feasibility of adding sigh to PSV. If positive, it will provide physicians with an effective addition to standard PSV for lung protection, able to reduce failure of assisted ventilation. PROTECTION will provide the basis for a future larger trial aimed at verifying the impact of PSV + sigh on 28-day survival and ventilator-free days
Articolo in rivista - Articolo scientifico
Intervention study; Mechanical ventilation; Positive-pressure ventilation; Pressure support; Recruitment; Sigh; Ventilator-induced lung injury; Weaning
English
460
Gli Autori indicati come "Membri del Collaboration Group" fanno parte del Protection Study Group
Mauri, T., Foti, G., Fornari, C., Constantin, J., Guerin, C., Pelosi, P., et al. (2018). Pressure support ventilation + sigh in acute hypoxemic respiratory failure patients: study protocol for a pilot randomized controlled trial, the PROTECTION trial. TRIALS, 19(1), 460 [10.1186/s13063-018-2828-8].
Mauri, T; Foti, G; Fornari, C; Constantin, J; Guerin, C; Pelosi, P; Ranieri, M; Conti, S; Tubiolo, D; Rondelli, E; Lovisari, F; Fossali, T; Spadaro, S; Grieco, D; Navalesi, P; Calamai, I; Becher, T; Roca, O; Wang, Y; Knafelj, R; Cortegiani, A; Mancebo, J; Brochard, L; Pesenti, A; Grasselli, G; Spinelli, E; Abbruzzese, C; Rona, R; Bronco, A; Villa, S; Gianni, S; Papoff, A; Pinciroli, R; Colombo, R; Sproccati, C; Mandelli, P; Villa, F; Patroniti, N; Brunetti, I; Ball, L; Volta, C; Lazzeri, M; Maragoni, E; Eleuteri, D; Bello, G; Dell'Anna, A; Garofalo, E; Bruni, A; Biamonte, E; D'Andrea, R; Querci, L; Pierucci, E; Spina, R; Mori, I; Tomeo, F; Mercat, A; Beloncle, F; Jochmans, S; Mazerand, S; Baboi, L; Yonis, H; Jabaudon, M; Godet, T; Jovaisa, T; Barnes, T; Tariq, U; Weiler, N; Schädler, D; Frerichs, I; García-de-Acilu, M; Vidal, A; Rosas, E; Calvo, C; Zhou, J; Karagiannis, S; Zisopoulou, V; Staikos, I; Noc, M; Fister, M; Radsel, P; Gregoretti, C; Sabella, I; Raineri, S
File in questo prodotto:
File Dimensione Formato  
10281-204974.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 1.1 MB
Formato Adobe PDF
1.1 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/204974
Citazioni
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
Social impact